Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 836-842, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-942965
ABSTRACT
Surgery is the main treatment for resectable esophageal squamous cell carcinoma. However, for patients with locally advanced lesions, surgery-based comprehensive treatment is the best treatment strategy. According to the results of some randomized controlled clinical studies and meta-analysis, preoperative neoadjuvant therapy is recommended to improve the survival rate of patients. Neoadjuvant therapy includes neoadjuvant chemotherapy, chemoradiotherapy, targeted therapy and immunotherapy. Great progress has been made in neoadjuvant therapy, but there are still many clinical problems that need to be solved urgently, including the efficacy and safety of neoadjuvant therapy, the choice of neoadjuvant regimen and treatment cycle, the best combination and advantages of multimodal treatment, and the selection of responders to treatment, etc. This article provides a systematic review of the latest developments and existing controversies in neoadjuvant therapy for esophageal squamous cell carcinoma.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Esofágicas
/
Esofagectomía
/
Terapia Combinada
/
Terapia Neoadyuvante
/
Quimioradioterapia
/
Carcinoma de Células Escamosas de Esófago
Tipo de estudio:
Ensayo Clínico Controlado
/
Revisiones Sistemáticas Evaluadas
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Gastrointestinal Surgery
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS